<div id="readability-page-1"><p>Warm Springs Advisors Inc. purchased a new stake in shares of  Boston Scientific Co. (NYSE:BSX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 7,296 shares of the medical equipment provider's stock, valued at approximately $652,000.</p><div><p><span></span><span>Get <strong>Boston Scientific</strong> alerts:</span></p></div><ul><li>3 Stocks Lifting 2025 Guidance Despite Market Jitters</li></ul><p>Other hedge funds also recently made changes to their positions in the company. Investment Management Corp VA ADV acquired a new position in  Boston Scientific in the fourth quarter worth approximately $25,000.  Colonial Trust Co SC grew its position in  Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after buying an additional 260 shares during the last quarter.  TFC Financial Management Inc. grew its position in  Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after buying an additional 210 shares during the last quarter.  Valley National Advisers Inc. grew its position in  Boston Scientific by 262.4% in the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after buying an additional 286 shares during the last quarter.  Finally, Fairway Wealth LLC acquired a new position in  Boston Scientific in the fourth quarter worth approximately $36,000. Institutional investors own  89.07% of the company's stock. </p><h2>Insider Activity</h2><p>In related news, EVP Jeffrey B. Mirviss sold 4,675 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the completion of the transaction, the executive vice president now owns 28,454 shares in the company, valued at approximately $2,966,329.50. This represents a 14.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president now directly owns 36,193 shares in the company, valued at approximately $3,441,592.37. This trade represents a 11.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 195,830 shares of company stock worth $20,043,415 over the last quarter. Insiders own  0.50% of the company's stock. </p><h2>Analyst Ratings Changes</h2><ul><li>Boston Scientific: Why This MedTech Giant Isn’t Slowing Down</li></ul><p>Several equities analysts have weighed in on the stock. Royal Bank of Canada lifted their price objective on shares of Boston Scientific from $116.00 to $120.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, April 24th. Piper Sandler lifted their price objective on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, February 3rd. Morgan Stanley lifted their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, May 16th. Erste Group Bank raised shares of Boston Scientific to a &#34;strong-buy&#34; rating in a research note on Thursday, May 8th. Finally, UBS Group lifted their target price on shares of Boston Scientific from $105.00 to $130.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, February 7th. Twenty-three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Boston Scientific  has a consensus rating of &#34;Buy&#34; and an average target price of $114.87.</p><p><b>Check Out Our Latest Stock Report on Boston Scientific</b></p><h2>Boston Scientific Price Performance</h2><ul><li>Medtronic Stock: Growth On Rise of the Cardiovascular Machines</li></ul><p>BSX stock opened at $104.49 on Friday. The company has a 50 day simple moving average of $99.97 and a 200 day simple moving average of $97.29. The stock has a market cap of $154.59 billion, a price-to-earnings ratio of 83.59, a P/E/G ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a 1 year low of $71.88 and a 1 year high of $107.17. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. </p><p>Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. During the same period in the prior year, the company earned $0.56 EPS. The firm's quarterly revenue was up 20.9% compared to the same quarter last year.  Research analysts anticipate that  Boston Scientific Co. will post 2.85 EPS for the current fiscal year. </p><h2>About Boston Scientific</h2> (Free Report)<p>Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Boston Scientific</li><li>Dividend King Proctor &amp; Gamble Is A Buy On Post-Earnings Weakness </li><li>Pfizer's 7.5% Dividend: Income Haven or House of Cards?</li><li>Stock Average Calculator      </li><li>3 Trades Members of Congress Are Making Right Now</li><li>3 Defense Stocks Set to Benefit From Increased Military Spending</li><li>TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Boston Scientific Right Now?</h2><p>Before you consider Boston Scientific, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.</p><p>While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Warm Springs Advisors Inc. has acquired a new stake in Boston Scientific Co. (NYSE:BSX), purchasing 7,296 shares valued at approximately $652,000 during the fourth quarter. Other hedge funds also increased their positions in the company. Insider transactions included sales by EVP Jeffrey B. Mirviss and SVP Vance R. Brown. Analysts have raised their price targets for Boston Scientific, with a consensus rating of "Buy" and an average target price of $114.87. The stock opened at $104.49, with a market cap of $154.59 billion.</p>

Warm Springs Advisors Inc. Takes $652,000 Position in Boston Scientific Co. (NYSE:BSX)